The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery (LUNG ART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00410683
Recruitment Status : Unknown
Verified November 2020 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was:  Active, not recruiting
First Posted : December 13, 2006
Last Update Posted : November 20, 2020
Sponsor:
Collaborators:
Intergroupe Francophone de Cancerologie Thoracique
The Christie NHS Foundation Trust
European Organisation for Research and Treatment of Cancer - EORTC
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving radiation therapy after surgery is more effective than no radiation therapy in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to no radiation therapy in treating patients with non-small cell lung cancer that has been completely removed by surgery.


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Other: clinical observation Procedure: adjuvant therapy Radiation: 3-dimensional conformal radiation therapy Phase 3

Detailed Description:

OBJECTIVES:

Primary

  • Compare the disease-free survival of patients with completely resected non-small cell lung cancer treated with conformal thoracic radiotherapy vs no radiotherapy.

Secondary

  • Determine the toxicity, in particular cardiac and pulmonary toxicity, of these regimens in these patients.
  • Compare the local control in patients treated with these regimens.
  • Determine patterns of recurrence in patients treated with these regimens.
  • Determine the overall survival of patients treated with these regimens.
  • Assess second cancers in patients treated with these regimens.
  • Assess prognostic factors and predictive factors of treatment effect on disease-free survival and overall survival of patients treated with these regimens.
  • Determine the cost per recurrence-free year of life.

OUTLINE: This is a multicenter, randomized study.

Patients are stratified according to participating center, prior chemotherapy (neoadjuvant alone vs adjuvant vs none), number of lymph stations involved (0 vs 1 vs ≥ 2), histology (squamous cell vs other), and use of pretreatment positron emission tomography scans (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
  • Arm II: Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to10 years.

PROJECTED ACCRUAL: A total of 700 patients will be accrued for this study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART]
Actual Study Start Date : February 2007
Actual Primary Completion Date : July 2018
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Radiotherapy
Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
 Other: clinical observation
Procedure: adjuvant therapy
Radiation: 3-dimensional conformal radiation therapy
Active Comparator: No radiotherapy
Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
 Other: clinical observation
Procedure: adjuvant therapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Disease-free survival (DFS) [ Time Frame: assessed up every 3 and 6 months after randomization, every 6 months for the fist three years and yearly afterward ]

Secondary Outcome Measures :
  1. Acute and late toxicity (with identification of predictive factors of toxicity) [ Time Frame: assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event ]
  2. Local control [ Time Frame: assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event ]
  3. Patterns of failure [ Time Frame: assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event ]
  4. Overall survival (OS) [ Time Frame: assessed up In case of death whatever the cause ]
  5. Second cancers [ Time Frame: Assessed up in case of event ]
  6. Prognostic and predictive factors of treatment effect on DFS and OS [ Time Frame: assessed up at the end of the study ]
  7. Cost per recurrence-free year of life [ Time Frame: Assessed up at the end of the study ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA :

  1. Histological evidence of non-small cell lung cancer (NSCLC)
  2. Complete resection by lobectomy, bilobectomy or pneumonectomy (i.e patients with positive margins) or extra-capsular mediastinal nodal extension breaching the surface of the pathological specimen should not to be included
  3. Mediastinal lymph node exploration (lymph node sampling or systematic dissection of lymph nodes at stations 2, 4 and 7 in case of upper/middle right-sided lung cancer; 4, 7, 8 and 9 in case of lower right-sided lung cancer; 5, 6 and 7 in case of upper left -sided lung cancer; 7, 8 and 9 in case of lower left-sided lung cancer is recommended)
  4. Pathologically or cytologically documented N2 mediastinal nodal involvement, at the time of surgery if no preoperative chemotherapy or before preoperative chemotherapy, according to the criteria of the joint AJCC and UICC classification, clinical N2 patients without cytological or histological documentation of mediastinal node involvement before preoperative chemotherapy can be included in the study if and only if, they have histologically confirmed N2 disease at the time of surgery
  5. Prior chemotherapy is allowed (pre-operative or post-operative adjuvant chemotherapy, or both)
  6. Patient aged ≥ 18 years
  7. Good Performance status (WHO ≤ 2)
  8. Fit enough to receive curative radiotherapy
  9. Adequate pulmonary function with post-operative FEV1 after surgery > 1 l or over 35% theoretical value
  10. Signed informed consent form

EXCLUSION CRITERIA:

  1. Documented metastases, (except for ipsilateral nodule(s) in a different lobe after pneumonectomy or bi-lobectomy)
  2. Major pleural or pericardial effusion
  3. Synchronous contra-lateral lung cancer
  4. Clinical progression during post-operative chemotherapy
  5. Previous chest radiotherapy
  6. Intention of concomitant chemotherapy during radiotherapy
  7. Weight loss in the previous 6 months before surgery ≥ 10 %
  8. Evidence of severe or uncontrolled systemic disease as judged by the investigator
  9. Recent (< 6 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease

  10. Current or past history of neoplasm other than non-small cell lung cancer diagnosed within the last 5 years, except :

    • basal cell carcinoma of the skin
    • in situ carcinoma of the cervix A patient diagnosed for another neoplasm 5 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected.
  11. Pregnancy or breast feeding or inadequate contraceptive measures during treatment
  12. Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls
  13. Patient deprived of freedom or under guardianship
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410683


Locations
Layout table for location information
France
Institut Gustave Roussy
Villejuif, Val De Marne, France, 94805
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Intergroupe Francophone de Cancerologie Thoracique
The Christie NHS Foundation Trust
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Layout table for investigator information
Study Chair: Cecile Le Pechoux, MD Gustave Roussy, Cancer Campus, Grand Paris
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT00410683    
Other Study ID Numbers: CDR0000523568
2006/1202 ( Other Identifier: CSET number )
PROTEGE-01/0601 ( Other Identifier: UNICANCER )
20671 ( Other Identifier: European Union )
IFCT - 0503 ( Other Identifier: IFCT )
UK11/NW/0075 ( Other Identifier: The Christie NHS Foundation Trust )
First Posted: December 13, 2006    Key Record Dates
Last Update Posted: November 20, 2020
Last Verified: November 2020
Keywords provided by Gustave Roussy, Cancer Campus, Grand Paris:
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms